Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ZBH Stock Forecast 2025-2026
$101.51
Current Price
$20.08B
Market Cap
Buy 11
Hold 17
Sell 2
Wall St Analyst Ratings
Distance to ZBH Price Targets
+47.8%
To High Target of $150.00
+17.2%
To Median Target of $119.00
+3.4%
To Low Target of $105.00
ZBH Price Momentum
+5.6%
1 Week Change
-9.6%
1 Month Change
-14.9%
1 Year Change
-3.9%
Year-to-Date Change
-18.1%
From 52W High of $123.96
+9.0%
From 52W Low of $93.10
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Zimmer Biomet (ZBH) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on ZBH and similar high-potential opportunities.
Latest ZBH Stock Price Targets & Analyst Predictions
Based on our analysis of 38 Wall Street analysts, ZBH has a neutral consensus with a median price target of $119.00 (ranging from $105.00 to $150.00). The overall analyst rating is Buy (6.9/10). Currently trading at $101.51, the median forecast implies a 17.2% upside. This outlook is supported by 11 Buy, 17 Hold, and 2 Sell ratings.
The most optimistic forecast comes from David Toung at Argus Research, projecting a 47.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ZBH Analyst Ratings
11
Buy
17
Hold
2
Sell
ZBH Price Target Range
Low
$105.00
Average
$119.00
High
$150.00
Current: $101.51
Latest ZBH Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ZBH.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 10, 2025 | Barclays | Matt Miksic | Underweight | Maintains | $112.00 |
| Feb 10, 2025 | Truist Securities | Richard Newitter | Hold | Reiterates | $113.00 |
| Feb 7, 2025 | Raymond James | Jayson Bedford | Outperform | Maintains | $119.00 |
| Feb 7, 2025 | Needham | Mike Matson | Hold | Reiterates | $0.00 |
| Feb 7, 2025 | RBC Capital | Shagun Singh | Outperform | Maintains | $125.00 |
| Feb 7, 2025 | JMP Securities | Andrew Boone | Market Outperform | Reiterates | $140.00 |
| Jan 29, 2025 | Needham | Mike Matson | Hold | Reiterates | $0.00 |
| Jan 23, 2025 | Stifel | Rick Wise | Buy | Maintains | $138.00 |
| Dec 18, 2024 | Truist Securities | Richard Newitter | Hold | Maintains | $118.00 |
| Dec 17, 2024 | JP Morgan | Robbie Marcus | Overweight | Upgrade | $128.00 |
| Dec 12, 2024 | Barclays | Matt Miksic | Underweight | Maintains | $118.00 |
| Nov 4, 2024 | RBC Capital | Shagun Singh | Outperform | Maintains | $125.00 |
| Nov 1, 2024 | Truist Securities | Richard Newitter | Hold | Maintains | $117.00 |
| Oct 31, 2024 | Needham | Mike Matson | Hold | Reiterates | $0.00 |
| Oct 31, 2024 | Wells Fargo | Larry Biegelsen | Equal-Weight | Maintains | $117.00 |
| Oct 15, 2024 | Oppenheimer | Steven Lichtman | Outperform | Maintains | $135.00 |
| Oct 14, 2024 | Raymond James | Jayson Bedford | Outperform | Maintains | $123.00 |
| Oct 8, 2024 | RBC Capital | Shagun Singh | Outperform | Maintains | $120.00 |
| Oct 3, 2024 | BTIG | Ryan Zimmerman | Buy | Maintains | $126.00 |
| Oct 1, 2024 | Evercore ISI Group | Vijay Kumar | In-Line | Maintains | $110.00 |
Zimmer Biomet Holdings, Inc. (ZBH) Competitors
The following stocks are similar to Zimmer Biomet based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Zimmer Biomet Holdings, Inc. (ZBH) Financial Data
Zimmer Biomet Holdings, Inc. has a market capitalization of $20.08B with a P/E ratio of 22.9x. The company generates $7.68B in trailing twelve-month revenue with a 11.8% profit margin.
Revenue growth is +4.3% quarter-over-quarter, while maintaining an operating margin of +23.2% and return on equity of +7.3%.
Valuation Metrics
Market Cap
$20.08B
Enterprise Value
$26.31B
P/E Ratio
22.9x
PEG Ratio
11.8x
Price/Sales
2.6x
Growth & Margins
Revenue Growth (YoY)
+4.3%
Gross Margin
+71.0%
Operating Margin
+23.2%
Net Margin
+11.8%
EPS Growth
-42.9%
Financial Health
Cash/Price Ratio
+2.6%
Current Ratio
1.9x
Debt/Equity
53.1x
ROE
+7.3%
ROA
+4.6%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Zimmer Biomet Holdings, Inc. (ZBH) Business Model
About Zimmer Biomet Holdings, Inc.
What They Do
Develops orthopedic and medical reconstructive products.
Business Model
Zimmer Biomet generates revenue through the development, manufacturing, and marketing of orthopedic reconstructive products, spinal solutions, and other medical devices. The company caters to an expanding market driven by an aging population and the demand for advanced joint and bone health solutions.
Additional Information
Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer Biomet operates in over 25 countries, highlighting its global influence. The company's focus on strategic acquisitions and continuous innovation ensures its competitive edge in the rapidly evolving medical devices market.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
17,000
CEO
Mr. Ivan Tornos
Country
United States
IPO Year
2001
Website
www.zimmerbiomet.comZimmer Biomet Holdings, Inc. (ZBH) Latest News & Analysis
Latest News
Quick Summary
Zimmer Biomet has acquired Paragon 28, strengthening its position in the high-growth foot and ankle orthopedic market. The transaction highlights Zimmer Biomet's commitment to expanding its medical device portfolio.
Why It Matters
Zimmer Biomet's acquisition of Paragon 28 enhances its foothold in a high-growth market, potentially boosting revenue and market share in the orthopedic sector.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
ZBH's Hips segment anticipates growth driven by its navigation solutions, particularly in direct anterior stems and surgical impactors.
Why It Matters
ZBH's growth in the Hips business indicates strong demand for its navigation solutions, potentially boosting revenue and market share, which can positively impact stock performance.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Zimmer Biomet Announces Webcast and Conference Call of First Quarter 2025 Financial Results
18 days ago
Quick Summary
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) will host its Q1 earnings conference call on May 5, 2025, at 8:30 a.m. The event will be webcast.
Why It Matters
Zimmer Biomet's upcoming earnings call could reveal insights into its financial performance and future outlook, impacting stock price and investor sentiment.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Zimmer Biomet is expanding globally to meet increasing demand in the musculoskeletal market.
Why It Matters
Zimmer Biomet's expansion signals growth potential in a high-demand market, potentially boosting revenue and market share, which can lead to increased investor confidence and stock performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Former Louisiana Attorney General Charles C. Foti, Jr. and KSF are investigating the proposed sale of Paragon 28, Inc. to Zimmer Biomet, offering shareholders $13.00 plus potential additional cash.
Why It Matters
The investigation into Paragon 28's sale to Zimmer Biomet may signal potential risks or challenges in the transaction, affecting shareholder value and market perception.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Zimmer Biomet Holdings, Inc. announced that its RibFix Advantage® Fixation System has received CE Mark certification, marking it as the first intrathoracic rib fixation system to achieve this.
Why It Matters
Zimmer Biomet's RibFix Advantage® receiving CE Mark certification enhances its market position in thoracic solutions, potentially boosting sales and investor confidence in future growth.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About ZBH Stock
What is Zimmer Biomet Holdings, Inc.'s (ZBH) stock forecast for 2025?
Based on our analysis of 38 Wall Street analysts, Zimmer Biomet Holdings, Inc. (ZBH) has a median price target of $119.00. The highest price target is $150.00 and the lowest is $105.00.
Is ZBH stock a good investment in 2025?
According to current analyst ratings, ZBH has 11 Buy ratings, 17 Hold ratings, and 2 Sell ratings. The stock is currently trading at $101.51. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ZBH stock?
Wall Street analysts predict ZBH stock could reach $119.00 in the next 12 months. This represents a 17.2% increase from the current price of $101.51. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Zimmer Biomet Holdings, Inc.'s business model?
Zimmer Biomet generates revenue through the development, manufacturing, and marketing of orthopedic reconstructive products, spinal solutions, and other medical devices. The company caters to an expanding market driven by an aging population and the demand for advanced joint and bone health solutions.
What is the highest forecasted price for ZBH Zimmer Biomet Holdings, Inc.?
The highest price target for ZBH is $150.00 from David Toung at Argus Research, which represents a 47.8% increase from the current price of $101.51.
What is the lowest forecasted price for ZBH Zimmer Biomet Holdings, Inc.?
The lowest price target for ZBH is $105.00 from at , which represents a 3.4% increase from the current price of $101.51.
What is the overall ZBH consensus from analysts for Zimmer Biomet Holdings, Inc.?
The overall analyst consensus for ZBH is neutral. Out of 38 Wall Street analysts, 11 rate it as Buy, 17 as Hold, and 2 as Sell, with a median price target of $119.00.
How accurate are ZBH stock price projections?
Stock price projections, including those for Zimmer Biomet Holdings, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 28, 2025 8:49 AM UTC